Abstract The impacts of the Association for Molecular Pathology vs. Myriad Supreme Court decision regarding patenting DNA segments and multi-gene testing on cancer genetic counseling practice have not been well described. We aimed to assess genetic counselors' perceptions of how their genetic testing-related practices for hereditary breast and/ or ovarian cancer (HBOC) changed after these events.
On June 13, 2013, the US Supreme Court announced their decision in the case of Association for Molecular Pathology (AMP) vs. Myriad that Ba naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated^("Association for Molecular Pathology v. Myriad Genetics" 2013), opening the genetic testing market to increased competition among testing companies for some of the most widely ordered genetic tests, most notably those for breast and ovarian cancer susceptibility. This decision occurred in the context of the widening availability of nextgeneration sequencing via multi-gene panels for hereditary cancer susceptibility (Domchek et al. 2013; Kurian and Ford 2015; Stadler et al. 2014) .
Each of these changes could significantly impact the practice of cancer genetic counseling, introducing variability in which genetic tests to order -single gene/syndrome vs. panel -and laboratories from which to order testing (Bradbury et al. 2015) . This variability is likely to be influenced by a range of clinically important factors such as genes included in a panel, turnaround time, rate of variants of uncertain significance; quality of test reports and customer service (Bradbury et al. 2015; Domchek et al. 2013; Kurian and Ford Electronic supplementary material The online version of this article (doi:10.1007/s10897-017-0099-2) contains supplementary material, which is available to authorized users.
2015; Rainville and Rana 2014; Stadler et al. 2014) . But, because guidelines for genetic counseling and testing in hereditary breast and ovarian cancer (Berliner et al. 2013) were written before the Supreme Court decision and broad availability of multi-gene panels, genetic counselors have limited guidance on how to make increasingly difficult decisions about matching the right test to the right patient and counsel patients on multi-gene tests (Bradbury et al. 2015; Fecteau et al. 2014; Kurian and Ford 2015; Rainville and Rana 2014) .
Importantly, cancer genetic counseling and testing also gained increased visibility during this time period (Borzekowski et al. 2014) . In May 2013, the actress Angelina Jolie published an Op-Ed piece in the New York Times disclosing her BRCA status (Jolie 2013) . This information was disseminated widely and quickly (Borzekowski et al. 2014) . Shortly thereafter, a major national 3rd party payer began requiring the involvement of genetics professionals in the ordering of specific genetic tests (including BRCA1/2). Anecdotal evidence suggested that these events increased demand for genetic counseling services, layering on the complexity of making decisions about emerging genetic tests while accommodating higher volumes of patients.
Genetic counselors have a long-standing history of integrating and adapting to changes in technology, expanding services to meet new demands and supporting other health care providers' access to new technologies (Wicklund and Trepanier 2014) . In the current health care climate and in the context of a growing profession, it is increasingly important to gather evidence to inform significant shifts in practice and actively work to promote integration of evidence-based methodologies into our practice (Kurian and Ford 2015) . To understand the clinical impact of these recent events and determine what types of guidance genetic counselors need in this new era of testing, we performed a cross-sectional survey based on clinical vignettes to assess the following research questions: 1) Given a hypothetical patient scenario, have genetic counselors' choices for first-line and reflex genetic testing for breast/ovarian cancer risk assessment changed since the introduction of multi-gene panels and the AMP v. Myriad Supreme Court decision? 2) Do genetic counselors perceive changes to the ways in which they order, evaluate and integrate genetic tests into their counseling?
3) In what ways have genetic counseling and testing changed since the introduction of multi-gene panels and the AMP v. Myriad Supreme Court decision? and 4) Are there factors which were associated with any of these changes?
Methods Participants
All practicing U.S. cancer genetic counselors in the National Society of Genetic Counselors (NSGC) Cancer Special Interest Group (SIG) who ordered a genetic test for hereditary breast/ ovarian cancer in the last month were eligible to participate.
Procedures
Members of the NSGC Cancer (SIG) were invited to participate in the study via a message sent to the SIG's discussion forum on November 5th -26th, 2013. During this time frame, there were 752 individuals on the distribution list. The message included a link to an anonymous online survey, which was administered via SurveyMonkey®, a commercial online survey system. During the 3 weeks for which the survey was available, we sent 2 reminder messages to the discussion forum. The study was exempted from review by the Ohio State University Institutional Review Board.
Instrumentation
The survey presented four hypothetical clinical vignettes developed by the authors to highlight different factors that could influence which genetic test to order (Supplemental Table S1 ). For each vignette, participants were asked to select the testing they would have ordered before and after the Supreme Court decision and availability of multi-gene panel testing (Supplemental Table S2 ). Ways in which clinical practice has changed were assessed via closed-ended items (e.g., BIn what ways has your practice changed in the last 12 months?^; BPlease rank the impact of the following events from greatest to least impact on your clinical practice in the last 12 months^) and open-ended items (BPlease describe any changes in your practice and any relevant reasons your practice has changed^). Closed-ended items were used to assess whether the type of test ordered and number of laboratories from which testing is ordered have changed. We used 5-point Likert scale items (completely, a lot, somewhat, a little, not at all) to assess the degree to which participants changed first-and second-line genetic testing choices since the Supreme Court decision, and for other reasons within the last year. To address research question 3 on factors influencing the type of genetic testing offered, we asked participants to rank eight factors from most important to least important: Patient's medical and family history, Likelihood of finding a variant of uncertain significance, Evidence-base to inform follow-up recommendations if pathogenic variants are identified, Insurance coverage, Patient preference, Whether the patient is newly diagnosed with cancer, Turn-around-time and Out of pocket cost to the patient. We addressed research question 4 on factors influencing choice of laboratory by asking participants to rank eight factors from most important to least important: Customer support, Cost to the patient's insurance company, Testing platform, Turn-around-time, Reputation of laboratory, Insurance Preauthorization Services, Out of pocket cost to the patient, Variant rates. All measures were developed by the authors based on expert opinion.
Demographic and practice variables assessed in the survey include work setting, sub-specialty, proportion of patients seen for hereditary breast/ovarian cancer evaluation, new patients seen per week, BRCA1/2 tests ordered per week, number of genetic counselors in participants' clinic, gender, age, region of practice, and years in practice.
Data Analyses
Responses from the survey yielded quantitative and qualitative data.
All quantitative analyses were conducted using SPSS 22.0. For all measured variables we calculated descriptive statistics (e.g., ranges, medians, means and standard deviations for continuous variables and frequencies for categorical variables). For comparison of categorical variables we used χ 2 tests to test for difference in answer distribution. For exploratory bivariate analyses comparing multiple groups to identify correlates of change, we used one-way ANOVA, testing for associations between years of practice, type of practice (academic vs. non-academic), number of genetic counselor coworkers, urban vs. rural location, NSGC region, and changes to genetic testing choice. We applied a p-value threshold of p ≤ 0.01 to account for multiple comparisons.
Qualitative Analyses
Conventional content analysis was used (Hsieh and Shannon 2005) .
Answers to all open-ended questions were reviewed and coded by two co-authors who coded each response together to ensure consensus. Each response was assigned a code phrase; similar codes were grouped into overall themes. Descriptive quotes were identified and reported to demonstrate each theme.
Results

Sample Characteristics
We received 152 complete survey responses for a conservative estimated response rate of 20%. Not all members of the Cancer SIG listserv were eligible to take the survey, namely non-clinical genetic counselors and those practicing outside of the U.S., as such this is likely an underestimate. Participants were demographically comparable to cancer genetic counselors who responded to the 2014 Professional Status Survey (NSGC 2014) ( Table 1) . Forty percent of the sample had been practicing for fewer than 5 years; 38% worked in a university medical center. One-third (35%) reported ordering 0-10 BRCA1/2 tests (including panels) per month, 44% order 11-20 and 35% order more than 20 tests.
Responses to Clinical Vignettes
We presented participants with four standardized patients seeking genetic testing and asked what they would have ordered for these patients prior to the introduction of multi-gene panel testing and prior to the AMP vs. Myriad Supreme Court decision, and what they might currently offer (Table 2) . Responses to questions regarding what they would have ordered as first-line tests prior to these events showed little variability, with the large majority (89% or more) of counselors choosing the same first-line test for each patient. Responses to the question of their current, first-line test choice (after the introduction of multi-gene panel testing and after AMP vs. Myriad) were much more varied, with no Bconsensus^answer for most questions.
Of the counselors ordering panels, there was also variation regarding choice of panel, impacted by the family and medical history of the patient. In the first vignette, depicting a newlydiagnosed, 37-year-old woman with breast cancer and one second degree relative with breast cancer, 35% of counselors would consider a breast cancer specific panel, including BRCA1/2, as a first-line test and 8% would order a general cancer gene panel including BRCA1/2. In the second vignette, depicting a 50-year-old, 5-year breast cancer survivor with a significant family history of early breast and ovarian cancer, 26% of counselors would consider a breast cancer specific panel, including BRCA1/2, as a first-line test and 24% would order a general cancer gene panel including BRCA1/2. In the third vignette, with the introduction of colon cancer on the paternal side, 40% of counselors selected the general cancer gene panel including BRCA1/2 and 20% selected the breast cancer specific panel including BRCA1/2.
Participants' choices for reflex testing -second-line testing performed after uninformative first-line testing, often to deletion/duplication testing or a larger panel -in the current period were similarly diverse. Many more counselors chose reflex testing when they previously would not have; before the availability of expanded panels and before AMP vs. Myriad, 99.5% of counselors would have stopped testing in vignette one if their first-line test came back negative. That figure dropped to 52% of participants choosing no further testing at the time of the survey. Of the counselors offering reflex testing in the first vignette, options they would consider include breast cancer specific panels, with BRCA1/2 (12%) without BRCA1/2 (23%) and broad cancer panels, with BRCA1/2 (23%) and without BRCA1/2 (15%). Similar patterns of choices were observed in the other three vignettes.
Changes to Genetic Counseling Practice
Almost all counselors surveyed (99%) felt that their practice had changed in the year prior to their completing the survey. We asked about the relative impact of four events on their practice: 1) the introduction of multi-gene panels for hereditary breast and ovarian cancer risk assessment; 2) The AMP vs. Myriad Supreme Court decision; 3) the op-ed piece in the New York Times by Angelina Jolie; and 4) changes in the counselors' ability to bill for services. Respondents most frequently endorsed expanded panels (45%) and the Supreme Court decision (44%) as having the greatest impact on their practice.
Genetic counselors were presented with a list of possible practice changes over the previous twelve months and asked to mark all that apply. Nearly all (95%) respondents reported that they experienced an increase in patient volume in the previous twelve months, with some participants noting increased wait times for appointments. We found that 35% reported an increase in the number of patients seen who had already had genetic testing (either through the genetic counselor or an outside clinician), 34% reported providing more post-test counseling by phone and 29% reported more office visits per patient.
Sixty-five genetic counselors expounded upon changes in their practice via qualitative feedback. The most frequent responses described changes in the content (n = 21) and length of genetic counseling sessions (n = 13), changes in which tests they offered (n = 16), more consideration about testing labs (n = 11), and explanations for increases in patient volume, wait times (n = 16) and workload (n = 12).
Participants indicated that the content of their pre-test counseling sessions has changed significantly over the last year. Not only have genetic counselors incorporated discussions about the availability of multi-gene panels into their sessions, they find that they spend less time discussing implications of each gene/syndrome (decreased depth) and more time discussing the range of information that can come from such tests (increased breadth), including unknown penetrance Vignette # 1
• 37-yo, newly-diagnosed with breast cancer
Vignette # 2
• 50-yo, diagnosed with breast cancer @ 45
• Northern European ancestry 12 (20) 18 (26) 8.5 (13) 11 (16) Breast specific panel (w/o BRCA1/2) 23 (37) 18 (26) 10 (15) 8 (12) Cancer gene panel (w/o BRCA1/2)
15 (25) 23 (33) 15 (23) 16.5 (25)
and management for Bnewer^genes on the panels and increased risks of variants of uncertain significance.
B[My practice has changed given] modifications to pretest counseling session; learning how to counsel about testing for a multitude of genes by using a few genes as an example but not going into great detail about each gene; spending a little more time on the idea of results leading to some level of uncertainty either due to a variant or a deleterious mutations in a newer gene.P articipants commonly mentioned increased length of time needed during pre-test counseling to discuss multiple genetic testing options and post-test counseling to explain complex results, partly due to increased rates of variants of uncertain significance.
BThere is a lot more time up front discussing variants and preparing people for the fact that we may find changes in genes that we do not know what to do about. The reports are complex, and post-test counseling takes longer. We usually give results by phone, but more patients have come in for follow-up in-person discussions.Q ualitative data indicate that the increased volume is driven by previously tested patients being referred back to discuss Bnew^testing options, increased physician referrals to genetic counselors and increased self-referrals and increases in family-member testing for known mutations. Some attribute the increase in self-referrrals to the Angelina Jolie editorial. Lastly, participants reported increased numbers of referrals prompted by insurers requiring genetics professionals be involved in BRCA1/2 testing. B[Our practice has changed in that] patients previously tested are also being referred back by their providers to determine if they need new panel tests.B
We have seen a slight increase in patient volume as some providers who were formerly offering direct in office [testing] now recognize the complexities regarding abundance of lab choices and so have chosen to refer to our program.Ô f the twelve participants describing an increase in workload over the past year, several clarified the nature of the increase. Beyond increased workload related to increased patient volume, genetic counselors note more time dealing with insurance issues related to multi-gene panels, including preauthorization paperwork, writing more letters of medical necessity and insurance appeals, and more research needed to understand new genes on multi-gene panels and variant results. One counselor noted that additional staff or support did not accompany the increase in patient volume.
Changes in Genetic Testing and Laboratory Choices
Nearly all (94%, 143/152) participants reported changing the type of tests they are ordering for hereditary breast and ovarian cancer in the last 12 months. The same proportion of respondents (94%) changed the number of companies from which they order genetic tests for HBOC risk assessment. About half (56%) of respondents reported that they order tests from 3 or more laboratories.
We asked genetic counselors to rank eight different factors that they consider when choosing a laboratory for genetic testing from most important to least important. There was significant variation in the factor that counselors cited as most important. The four factors ranked most as most important by the greatest percentage of respondents were: reputation of the laboratory (27% ranked #1), insurance preauthorization services (22%), out-of-pocket costs to the patient (19%) and the testing platform (17.5%). When asked to rank factors important for choosing a specific test, most (73.5%) counselors listed Bpatients' medical and family history^as being most important.
Forty-two respondents provided insight on how and why their choice of genetic test and laboratory have changed. The most common changes described were increased use of panel testing (n = 19), ordering panel testing as a first-line test (n = 11), performing in-depth research on the laboratories that offer panel testing (n = 6), and using more laboratories (n = 8).
Participants listed several reasons for why they are now using panel testing, including the patient's clinical history (n = 15), cost-effectiveness (n = 6), and increased detection rate and information (n = 4). Some genetic counselors explicitly stated that they are now having a discussion about panel testing with all patients, while others expressed uncertainty about offering multi-gene panels.
BI am ordering more panel tests for patients who I suspect will be BRCA1/2 negative either because there is no ovarian cancer in the family or ages of diagnosis are not quite what you would expect. I made these changes because testing is available now, most insurers are covering it, and the results could be potentially useful in the future. I talk about panels with everyone and carefully explain the limitations and high VUS rate with everyone.B …with the addition of panels, we are finding that our old clinical criteria maybe weren't as accurate as we thought, so now I constantly wonder what I am missing. I feel like I don't have a good idea of who should, or shouldn't, be offered panel testing anymore.Ŝ everal participants stated they do not order panel testing as a first-line test if the patient is considering making a surgical decision based on the test results (n = 6). In these situations, the genetic counselor continues to offer single gene/syndrome testing as the first-line test.
BOur surgeons have been very vocal (to the patients and to myself) that they do not want TAT [turn-around-time] to change, so many newly-diagnosed, surgical patients are requesting single gene testing over panel testing.Ĝ enetic counselors stated that they are now researching more labs regarding the various panel tests that are offered (n = 4), the lab's internal data, accuracy, and reliability (n = 3), and cost and insurance coverage (n = 2). Genetic counselors indicated that the most common reason they are researching labs is to offer the most appropriate test at the most appropriate lab for each patient's personal situation based on their insurance coverage and comfort level with genetic testing. Genetic counselors are now using a greater number of labs. The choice of laboratory appears to consider many variables such as customer service (n = 3), educational materials (n = 2), the type and number of genes in panels (n = 3), whether a lab shares data with public databases (n = 1), cost and insurance coverage (n = 3), as well as soliciting patient input during the appointment (n = 1).
BI feel that laboratory data is the most important factor in choosing a lab...My number 1 concern is test accuracy…Patients are making medical decisions based on the information provided by the laboratory and false negatives or incorrectly interpreted variants (based only on literature searches) are a huge concern for me… We will put ourselves at increased liability for choosing an inferior laboratory that is missing numerous mutations even if their list price is cheaper...B
[My practice has changed in that I have] multiple options for panels through different labs and trying to keep track of which one works for which patient…However, [it is] amazing to be able to offer these options for patients in a comprehensive test including BRCA.Ĉ
orrelates of Change
To identify correlates of change among participants, we tested for associations between years of practice, type of practice (academic vs. non-academic), number of genetic counselor coworkers, urban vs. rural location, NSGC region, and changes to genetic testing, measured by number of changed preferences in the vignettes and also self-reported magnitude of change. Of the variables tested, significant between-group differences were noted by NSGC region across both measures of change. In their responses to the four vignettes, the number of times participants changed their preferences from the BBefore^question in response to the BCurrently^questions was tallied. The distribution of these tallies varied by region (Fig. 1a, F=3 .13, p = 0.01). We also compared self-reported degree of change on a 5-point Likert scale (BA Lot^to BNone at all^) and found this to differ by region as well, with Region 2 reporting the least amount of perceived change (Fig. 1b,  F=6 .15, p < 0.001). There were no other statistically significant findings at a p-value threshold of p ≤ 0.01.
Discussion
To capture the impact of key developments in cancer genetic counseling and testing, we surveyed US cancer genetic counselors about current and past practices. Genetic counselors reported large-scale changes in their counseling and testing practices. Across four different hypothetical patients, at least half of all participants changed their test preferences for firstline testing and reflex genetic testing following the US Supreme Court AMP v. Myriad decision and in response to the introduction of multi-gene panel tests. Further, nearly all participants reported changing the way they order tests and the labs from which they order tests. This change reflects a fairly rapid dissemination of new technology within a field, likely driven by a number of factors. Further, respondents varied considerably in their choices of tests following the court decision and introduction of multi-gene panels, indicating that the change was not a shift toward a particular test or standard of care, but rather increased utilization of a number of different testing options and algorithms.
We also found regional differences in both hypothetical preferences for new testing options and self-reported degree of change. Regional differences have been noted previously for behaviors like breast-conserving therapy (Habermann et al. 2010; Nattinger et al. 1992) . It is possible a similar effect is at play in our study. Other possible sources of variation include cultural differences, regional differences in 3rd party payer policies, and differences in preferences of the counselors' overall patient populations. Further studies are warranted to better understand this effect.
Genetic counselors have a long-standing history of actively working to integrate new genetic technologies into clinical care (Wicklund and Trepanier 2014) . As such, it is not surprising to see a rapid rate of dissemination in this population. Our qualitative data provide additional detail as to how practice is changing in and out of sessions to accommodate new genetic tests and testing options. Reflecting the broader scope of new tests and rates of variants of uncertain significance as high as 40% (LaDuca et al. 2014; Tung et al. 2015) , counselors are spending more time talking about uncertainty. They also reported that they are spending more time in general with patients -in pre-test sessions, in follow up sessions and on the phone. This highlights the value of genetic counselors in selecting and interpreting cancer genetic tests, and raises questions about how this time should be reimbursed by 3rd party payers, or whether current models can sustain this level of service.
Practice Implications and Research Recommendations
As supported by our data, cancer genetic counselors presented an ideal population in which to study dissemination of new genetic tests, given the uniformity of testing preferences that existed towards the end of the previous decade followed by a number of closely linked events bringing significant changes. Significant resources were invested over the last 20 years into building the evidence base for BRCA1/2 testing, allowing for several well-supported guidelines directing clinicians whom to offer testing to and when. At present, while evidence is starting to gather regarding testing outcomes from gene panels at the level of single institutional experiences (Mauer et al. 2014; Selkirk et al. 2014 ) and laboratory experiences (LaDuca et al. 2014; Tung et al. 2015) , the evidence base has yet to inform algorithms that can guide the selection of specific multi-gene tests according to patients' personal history, family history and preferences. This is a likely cause of much variation in practice observed in this study.
Development of an evidence base that could guide clinical care regarding next-generation sequencing should focus on clinical issues such as better defining the tumor spectrum and penetrance for moderate-penetrance genes (e.g., via registries such as the PROMPT registry (www.promptstudy.org)) , more thorough curation of gene variants (e.g., via ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) and studies such as ClinGen (http://www.clinicalgenome.org)), and the rate of incidental findings on multi-gene tests. This evidence base should be supplemented by research on genetic counseling issues such as assessing patients' preferences on how to discuss multi-gene panels, especially whether the Bbreadth over depth^approach described in this study resonates with patients. It would also be instructive to determine what factors patients value when selecting a genetic test. Finally, given that the majority of genetic counselors completed their training programs prior to the advent of multi-gene panels (NSGC 2014) , it would be helpful to determine counselors' continuing education needs regarding next-generation sequencing.
Study Limitations
The age, gender and work settings of study participants are comparable to the much larger sample (n = 352) of cancer genetic counselors who responded to the 2014 Professional Status Survey (NSGC 2014). The study draws from selfreported practices and experiences and, as such, is subject to potential bias. Further, we asked genetic counselors to report their recollections of testing practices prior to the US Supreme Court decision; these answers may be subject to recall bias. Future studies might employ study designs that avoid these potential biases by prospectively tracking actual test ordering behavior and other clinic statistics. Measuring changes to session content could be done with audio recordings of the actual or simulated sessions (Butrick et al. 2014; Roter et al. 2006 ). It will also be important to capture patient outcomes of different counseling techniques, to understand how clinicians can best address complex testing scenarios and the often related topic of uncertainty and promote patient understanding and adaptation to cancer risk.
This study provides qualitative and quantitative pictures of the complex decision making that occurs in selection of test and laboratory, highlighting areas of change and professional uncertainty among genetic counselors. At the same time, we provide evidence for the adaptability of genetic counseling practice to new genetic technologies, in time periods of technological advancement, and the roles that genetic counselors play in integrating complicated new tests into clinical practice.
